<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/><meta name="exporter-version" content="Evernote Mac 7.14 (458244)"/><meta name="author" content="taylor.arhar@gmail.com"/><meta name="created" content="2019-04-17 21:15:01 +0000"/><meta name="source" content="desktop.mac"/><meta name="updated" content="2019-04-17 21:27:36 +0000"/><title>April 11, 2019</title></head><body><div>DJA1 purification day 3:</div><div>- GOALS: repeat reverse purification, run DJA1 (cleaved or not) on SEC200, test fractions for protein</div><div>- reverse purification was performed as previously described; a sample of each fraction was tested by gel to determine cleavage efficiency and the location of DJA1 in solution (see attached)</div><div>- as the majority of DJA1 eluted from the resin (rather than being present in the flowthrough), eluted protein was concentrated to a final volume of ~5mL using 30kDa MWCO spin tubes</div><div>- DJA1 was run onto SEC200</div><div>- SEC200 fractions with high A280 were tested by gel (see attached)</div><div>- RESULTS: the majority of DJA1 eluted in fractions that likely correspond to dimeric state, as opposed to the void fractions; this suggests that either (a) the low concentration of the sample, due to sample loss over many steps, resulted in less aggregation or (b) the addition of DNase and RNase throughout the purification contributed to solubilizing the protein</div><div><img src="April%2011,%202019.html.resources/2019-04-11%2014h34m56s%20Coomassie%20Blue(Coomassie%20Blue).tif" >041119 K18 FKBP12 HSQC buffer BCA.xlsx</a><br/></div><div><br/></div></body></html>
